David Gandara, Co-Director-Center for Experimental Therapeutics at UC Davis Comprehensive Cancer Center, shared a post on X:
“ODAC for the AEGEAN perioperative trial held today. WOW on mandating additional trials defining contribution of components when FDA has already approved KN671, with same design issue. No vote taken on approval or not? Consistency?”
Source: David Gandara/X